PE20240233A1 - Fracciones que prolongan la semivida y metodos de uso de estas - Google Patents

Fracciones que prolongan la semivida y metodos de uso de estas

Info

Publication number
PE20240233A1
PE20240233A1 PE2023002220A PE2023002220A PE20240233A1 PE 20240233 A1 PE20240233 A1 PE 20240233A1 PE 2023002220 A PE2023002220 A PE 2023002220A PE 2023002220 A PE2023002220 A PE 2023002220A PE 20240233 A1 PE20240233 A1 PE 20240233A1
Authority
PE
Peru
Prior art keywords
seq
amino acid
group
acid sequence
present
Prior art date
Application number
PE2023002220A
Other languages
English (en)
Inventor
Andrea Ferrante
Josef George Heuer
Stacey Lynn Lee
Petra Verdino
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20240233A1 publication Critical patent/PE20240233A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

La invencion se refiere a un compuesto que comprende una estructura de: M-X1, X1-M, M-L1-X1, X1-L1-M, X1-M-X2, X2-M-X1, X1-L1-M-X2, entre otros; en donde M es una secuencia de aminoacidos seleccionada del grupo que consiste en las SEQ ID NO: 1-37 y 124-126, o al menos aproximadamente 90 % de similitud de secuencia con esta; X1 es un primer biofarmaco; X2 (si esta presente) es un segundo biofarmaco; L1 (si esta presente) es un primer enlazador que tiene una secuencia de aminoacidos seleccionada del grupo que consiste en (GGGGQ)n (SEQ ID NO: 38), (GGGQ)n (SEQ ID NO: 39), entre otros; y L2 (si esta presente) es un segundo enlazador que tiene una secuencia de aminoacidos seleccionada del grupo que consiste en SEQ ID NO: 64 y 65, o al menos aproximadamente 90 % de similitud de secuencia con estas. Dicho compuesto actua como fracciones que prolongan la semivida (t1/2) para biofarmacos o productos biologicos, basada en anticuerpos de un solo dominio, dominios variables de anticuerpos solo de cadena pesada (VHH). Tambien se refiere a fusiones y conjugados que incluyen dicho compuesto, asi como composiciones farmaceuticas que las incluyen y su uso en el tratamiento de diversas afecciones, enfermedades o trastornos.
PE2023002220A 2021-02-02 2022-02-01 Fracciones que prolongan la semivida y metodos de uso de estas PE20240233A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163144696P 2021-02-02 2021-02-02
PCT/US2022/014728 WO2022169757A1 (en) 2021-02-02 2022-02-01 Half-life extending moieties and methods of using the same

Publications (1)

Publication Number Publication Date
PE20240233A1 true PE20240233A1 (es) 2024-02-16

Family

ID=80735776

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023002220A PE20240233A1 (es) 2021-02-02 2022-02-01 Fracciones que prolongan la semivida y metodos de uso de estas

Country Status (15)

Country Link
EP (1) EP4288452A1 (es)
JP (1) JP2024506145A (es)
KR (1) KR20230137342A (es)
CN (1) CN116802209A (es)
AU (1) AU2022217754A1 (es)
CA (1) CA3204225A1 (es)
CL (1) CL2023002285A1 (es)
CO (1) CO2023010002A2 (es)
CR (1) CR20230366A (es)
DO (1) DOP2023000149A (es)
EC (1) ECSP23058246A (es)
IL (1) IL304219A (es)
MX (1) MX2023009006A (es)
PE (1) PE20240233A1 (es)
WO (1) WO2022169757A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310340A (en) * 2016-12-07 2024-03-01 Ablynx Nv Immunoglobulin sites with a single variable enhance serum albumin binding
US11384141B2 (en) * 2018-04-24 2022-07-12 National Research Council Of Canada Serum albumin binding antibodies for tuneable half-life extension of biologics
TW202120536A (zh) * 2019-07-31 2021-06-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法

Also Published As

Publication number Publication date
CR20230366A (es) 2023-10-03
CA3204225A1 (en) 2022-08-11
JP2024506145A (ja) 2024-02-09
WO2022169757A1 (en) 2022-08-11
EP4288452A1 (en) 2023-12-13
IL304219A (en) 2023-09-01
CO2023010002A2 (es) 2023-09-08
DOP2023000149A (es) 2023-09-15
CN116802209A (zh) 2023-09-22
MX2023009006A (es) 2023-08-08
KR20230137342A (ko) 2023-10-04
AU2022217754A1 (en) 2023-07-27
ECSP23058246A (es) 2023-09-29
CL2023002285A1 (es) 2024-02-23

Similar Documents

Publication Publication Date Title
PE20190911A1 (es) Composiciones y anticuerpos anti-lag-3
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
PE20181044A1 (es) Anticuerpos anti-pd-1 y composiciones
Li et al. The 9-fluorenylmethoxycarbonyl (Fmoc) group in chemical peptide synthesis–its past, present, and future
AR126242A2 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
CN105848746B (zh) 用于层析重复利用的方法
ECSP14011269A (es) Formulaciones de anticuerpos y proteínas de alta concentración
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
PE20181952A1 (es) Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos
AR110101A1 (es) Miembros de unión (2)
ES2689746T3 (es) Anticuerpos monoclonales contra la claudina-18 para el tratamiento de cáncer
AR076349A1 (es) Peptido auxiliar del antigeno del cancer
AR048989A1 (es) Metodos y composiciones para modular la expresion en plantas
AR068767A1 (es) Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
CO6150192A2 (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos
PE20081478A1 (es) Anticuerpos cd44
AR035539A1 (es) Moleculas de enlace capaces de enlazarse a isoformas cd45, polinucleotidos codificantes, un vector de expresion, un sistema de expresion, una celula huesped, el uso de dichas moleculas para la produccion de un medicamento y composiciones farmaceuticas.
AR046833A1 (es) Anticuerpos anti-interleuquina-10
SI2542257T1 (en) Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
AR072039A1 (es) Anticuerpos contra el virus de la hepatitis c
PE20201171A1 (es) Anticuerpos de cadena pesada que se unen a cd22
AR109450A1 (es) Moléculas de unión a ilt7 y métodos de uso de las mismas
EA200701947A1 (ru) Легкая фармацевтическая вода, терапевтические композиции, ее содержащие, способы их производства и применения
PE20220489A1 (es) Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso
PE20021098A1 (es) ANTICUERPOS ESPECIFICOS DE CD44v6